GemOx
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin's lymphoma.
When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.
The [R]-GemOx regimen consists of:
- (R)ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
- (Gem)citabine - an antimetabolite;
- (Ox)aliplatin - a platinum-based alkylating antineoplastic agent.[1][2]
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| (R)ituximab | 375 mg/m2 | IV infusion | Day 1 |
| (Gem)citabine | 1000 mg/m2 | IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min | Day 2 |
| (Ox)aliplatin | 100 mg/m2 | IV infusion over 2hrs | Day 2 |
gollark: Or alternately no language restrictions.
gollark: It seems a bit arbitrary imposing language restrictions.
gollark: What does this olympiad thing involve and why are you doing it?
gollark: That sounds horristupid.
gollark: What *are* accepted languages then?
References
- GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II study
- Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.